Skip to content
Screener

Zimmer Biomet Holdings ZBH Research and development expense

Research and development expense at other companies

Medtronic logo
MedtronicMDT
Alphatec Holdings logo
Alphatec HoldingsATEC

Segments

By geography

See full
Americas$71.1M-3.4%
Asia Pacific$3.9M+11.4%
EMEA$1.9M+11.8%

Other financials

Income statement

See full
Revenue$2.2B+4.8%
Gross profit$1.5B+3.8%
Operating income$326.1M+8.7%
Net income$198.3M+29.8%
EPS (diluted)$1.03+33.8%

Balance sheet

See full
Cash & equivalents$410.0M-26.4%
Total debt$7.5B-1.2%
Total equity$12.6B+0.8%
Total assets$22.8B-0.3%

Cash flow

See full
Operating cash flow$447.8M+18.4%
CapEx$54.2M+8.2%
Free cash flow$393.6M+20.0%

Valuation

See full
Market cap$18.99B+5.3%
Enterprise value$26.06B+4.0%
P/E23.5×+1.6×
P/S2.2×-0.1×

Profitability

See full
Gross margin69.9%-1.2pp
Operating margin14.2%-1.9pp
Net margin9.5%-1.0pp
FCF margin17.9%-0.9pp

Returns & leverage

See full
Return on equity6.4%-0.1pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.2×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Zimmer Biomet Holdings’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335044
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net Sales$2,177.0$2,077.3$4,263.7$3,986.4
Cost of products sold, excluding intangible asset amortization635.5592.21,211.61,142.0
Intangible asset amortization163.4160.6325.5311.6
Research and development104.8113.3208.2223.9
Selling, general and administrative899.3814.81,749.31,573.5
Restructuring and other cost reduction initiatives29.817.536.153.5
Acquisition, integration, divestiture and related18.178.933.789.5
Operating expenses1,850.91,777.33,564.43,394.0

Item 1. Financial Statements

FAQ

What is Zimmer Biomet Holdings's research and development expense?
Zimmer Biomet Holdings (ZBH) reported research and development expense of $104.8M in Q2 2026.
How has Zimmer Biomet Holdings's research and development expense changed year-over-year?
Zimmer Biomet Holdings's research and development expense decreased by 7.5% year-over-year, from $113.3M to $104.8M.
What is the long-term trend for Zimmer Biomet Holdings's research and development expense?
Over 4 years (2021 to 2025), Zimmer Biomet Holdings's research and development expense has grown at a 1.3% compound annual growth rate (CAGR), from $435.8M to $458.5M.
What does research and development expense mean?
Research and development expense

Ask your AI about Zimmer Biomet Holdings's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude